Bachem refines peptide focus, shares under analyst scrutiny
25.06.2026 - 16:47:03 | ad-hoc-news.de
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-25, 16:46.
Bachem (CH0012530207) is attracting attention among biotech investors as a specialized peptide and oligonucleotide manufacturer on the SIX Swiss Exchange. Analyst commentary and consensus estimates highlight a careful balance between growth expectations and valuation for the mid-cap CDMO player.
What analysts currently say
Broker coverage collected on platforms such as MarketScreener and finanzen.ch shows that several houses rate Bachem between Hold and Buy, reflecting both its strong niche and execution risks in large projects. According to these consensus snapshots, the average analyst stance remains cautiously constructive for the Swiss peptide group.
Recent notes cited by Swiss financial portals point to Bachem’s order visibility in peptide and oligonucleotide projects for pharma and biotech customers as a key driver. At the same time, analysts emphasize that capacity expansion and project ramp-up carry execution risks typical for contract development and manufacturing organizations in life sciences.
Consensus expectations for growth
Consensus data compiled by MarketScreener indicate that analysts expect Bachem to grow revenue over the coming years as demand for complex peptides and oligonucleotides rises in drug development. Several estimates referenced there see mid- to high-single-digit annual growth as a realistic base case under current assumptions.
Finanzen.ch summarizes that the company’s profitability is expected to benefit gradually from operating leverage once recent investments in manufacturing capacity are better utilized. However, some analysts referenced on these platforms warn that a slower ramp of individual large orders could lead to temporary margin pressure, which is reflected in more neutral ratings.
All news and data on the Bachem shares
Key figures, past reports and further updates on Bachem are available in the dedicated topic area and on the company’s investor relations pages.
How Bachem makes its money
Bachem generates revenue primarily by developing and manufacturing complex peptides and oligonucleotides for pharmaceutical and biotechnology customers as an outsourcing partner. The company offers custom synthesis and commercial-scale production for use in active pharmaceutical ingredients and research applications, focusing on high-quality, regulated supply.
Where the stock trades today
The Bachem shares (CH0012530207) trade on the SIX Swiss Exchange in Zurich; the last available quotation for the stock showed the price in Swiss francs on the same trading day as the consensus data used in this article.
Key data on the Bachem shares
- Company: Bachem Holding AG
- ISIN: CH0012530207
- WKN: 902453
- Ticker: BANB
- Trading venue: SIX Swiss Exchange
- Price (as of latest available quotation): [current price] CHF
- Market cap: [current market capitalization] CHF (as of same date)
- Sector / industry: Healthcare / Biotechnology / CDMO
- Index membership: SPI
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. All data are based on publicly available sources and may change without notice.
